Cite
HARVARD Citation
Nicolaides, N. et al. (2018). CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients. Cancer biology & therapy. 19 (7), pp. 622-630. [Online].